Renaissance Technologies LLC Sells 194,440 Shares of Protara Therapeutics, Inc. (NASDAQ:TARA)

Renaissance Technologies LLC lessened its holdings in shares of Protara Therapeutics, Inc. (NASDAQ:TARA - Free Report) by 57.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 142,300 shares of the company's stock after selling 194,440 shares during the quarter. Renaissance Technologies LLC owned about 0.69% of Protara Therapeutics worth $751,000 at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in the business. Bailard Inc. purchased a new position in Protara Therapeutics during the fourth quarter valued at $157,000. Commonwealth Equity Services LLC increased its holdings in shares of Protara Therapeutics by 90.4% in the fourth quarter. Commonwealth Equity Services LLC now owns 37,000 shares of the company's stock worth $195,000 after purchasing an additional 17,572 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Protara Therapeutics by 21.0% in the third quarter. Geode Capital Management LLC now owns 170,040 shares of the company's stock worth $311,000 after buying an additional 29,514 shares in the last quarter. ADAR1 Capital Management LLC bought a new position in Protara Therapeutics during the fourth quarter valued at approximately $648,000. Finally, Oppenheimer & Co. Inc. grew its holdings in Protara Therapeutics by 12.4% during the 4th quarter. Oppenheimer & Co. Inc. now owns 201,426 shares of the company's stock valued at $1,064,000 after buying an additional 22,301 shares in the last quarter. 38.13% of the stock is owned by hedge funds and other institutional investors.

Protara Therapeutics Stock Down 0.9 %

TARA traded down $0.03 during trading hours on Wednesday, reaching $3.34. 251,951 shares of the company's stock traded hands, compared to its average volume of 787,264. The firm has a 50-day moving average price of $4.00 and a 200 day moving average price of $4.07. The firm has a market capitalization of $128.85 million, a PE ratio of -1.18 and a beta of 1.73. Protara Therapeutics, Inc. has a 52-week low of $1.60 and a 52-week high of $10.48.

Protara Therapeutics (NASDAQ:TARA - Get Free Report) last posted its quarterly earnings results on Wednesday, March 12th. The company reported ($0.48) EPS for the quarter, topping analysts' consensus estimates of ($0.57) by $0.09. Equities analysts predict that Protara Therapeutics, Inc. will post -3.32 EPS for the current fiscal year.

Insider Activity at Protara Therapeutics

In other Protara Therapeutics news, insider Jacqueline Zummo sold 21,224 shares of Protara Therapeutics stock in a transaction on Wednesday, March 26th. The stock was sold at an average price of $4.53, for a total transaction of $96,144.72. Following the completion of the sale, the insider now directly owns 98,861 shares of the company's stock, valued at $447,840.33. The trade was a 17.67 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 12.50% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the stock. HC Wainwright restated a "buy" rating and issued a $23.00 price target on shares of Protara Therapeutics in a research report on Monday, April 28th. Scotiabank started coverage on Protara Therapeutics in a research report on Wednesday, April 16th. They set a "sector outperform" rating and a $12.00 price objective on the stock. Cantor Fitzgerald assumed coverage on Protara Therapeutics in a report on Friday, March 14th. They issued an "overweight" rating for the company. Finally, Lifesci Capital initiated coverage on Protara Therapeutics in a research report on Tuesday, March 11th. They issued an "outperform" rating and a $22.00 price target for the company. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $20.40.

Protara Therapeutics Profile

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.